Terms: = Sarcomas AND PAX3, MGC120382, 5077, ENSG00000135903, CDHS, MGC120383, HUP2, P23760, WS1, MGC120384, MGC134778, MGC120381
472 results:
1. FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma.
de Traux De Wardin H; Cyrta J; Dermawan JK; Guillemot D; Orbach D; Aerts I; Pierron G; Antonescu CR
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23232. PubMed ID: 38607246
[TBL] [Abstract] [Full Text] [Related]
2. Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Martin-Giacalone BA; Li H; Scheurer ME; Casey DL; Dugan-Perez S; Marquez-Do DA; Muzny D; Gibbs RA; Barkauskas DA; Hall D; Stewart DR; Schiffman JD; McEvoy MT; Khan J; Malkin D; Linardic CM; Crompton BD; Shern JF; Skapek SX; Venkatramani R; Hawkins DS; Sabo A; Plon SE; Lupo PJ
JAMA Netw Open; 2024 Mar; 7(3):e244170. PubMed ID: 38546643
[TBL] [Abstract] [Full Text] [Related]
3. CRISPR-Cas9-Mediated Bioluminescent Tagging of Endogenous Proteins by Fluorescent Protein-Assisted Cell Sorting.
Hawley RG; Hawley TS
Methods Mol Biol; 2024; 2779():273-286. PubMed ID: 38526790
[TBL] [Abstract] [Full Text] [Related]
4. Transforming Growth Factor Beta and Alveolar Rhabdomyosarcoma: A Challenge of Tumor Differentiation and Chemotherapy Response.
Bhushan B; Iranpour R; Eshtiaghi A; da Silva Rosa SC; Lindsey BW; Gordon JW; Ghavami S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474036
[TBL] [Abstract] [Full Text] [Related]
5. KDM3B inhibitors disrupt the oncogenic activity of pax3-FOXO1 in fusion-positive rhabdomyosarcoma.
Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
[TBL] [Abstract] [Full Text] [Related]
6. Treatment of nasolabial fold rhabdomyosarcoma in children: A single-institution experience.
Zhang G; Sun N; Ni X; Su Y; He L; Liu Z; Zhang J; Li Y; Zhang X; Liu Q; Liu Z; Li X; Mei L; Liu Y; Ji T; Wang S
Head Neck; 2024 Apr; 46(4):905-914. PubMed ID: 38214480
[TBL] [Abstract] [Full Text] [Related]
7. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57
Pomella S; Cassandri M; D'Archivio L; Porrazzo A; Cossetti C; Phelps D; Perrone C; Pezzella M; Cardinale A; Wachtel M; Aloisi S; Milewski D; Colletti M; Sreenivas P; Walters ZS; Barillari G; Di Giannatale A; Milano GM; De Stefanis C; Alaggio R; Rodriguez-Rodriguez S; Carlesso N; Vakoc CR; Velardi E; Schafer BW; Guccione E; Gatz SA; Wasti A; Yohe M; Ignatius M; Quintarelli C; Shipley J; Miele L; Khan J; Houghton PJ; Marampon F; Gryder BE; De Angelis B; Locatelli F; Rota R
Nat Commun; 2023 Dec; 14(1):8373. PubMed ID: 38102140
[TBL] [Abstract] [Full Text] [Related]
8. pax3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution.
Asante Y; Benischke K; Osman I; Ngo QA; Wurth J; Laubscher D; Kim H; Udhayakumar B; Khan MIH; Chin DH; Porch J; Chakraborty M; Sallari R; Delattre O; Zaidi S; Morice S; Surdez D; Danielli SG; Schäfer BW; Gryder BE; Wachtel M
Nat Commun; 2023 Dec; 14(1):8361. PubMed ID: 38102136
[TBL] [Abstract] [Full Text] [Related]
9. pax3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
[TBL] [Abstract] [Full Text] [Related]
10. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
[TBL] [Abstract] [Full Text] [Related]
11. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
[TBL] [Abstract] [Full Text] [Related]
12. Piperacetazine Directly Binds to the pax3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
[TBL] [Abstract] [Full Text] [Related]
13. Functional Genomics of Novel Rhabdomyosarcoma Fusion-Oncogenes Using Zebrafish.
Kent MR; Silvius K; Kucinski J; Calderon D; Kendall GC
Methods Mol Biol; 2024; 2707():23-41. PubMed ID: 37668903
[TBL] [Abstract] [Full Text] [Related]
14. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
[TBL] [Abstract] [Full Text] [Related]
15. Novel pax3::INO80D Fusion in Biphenotypic Sinonasal Sarcoma in an Adult.
Viramontes A; Mueller N; Gocke CD; Deklotz TR; Ozdemirli M
JAMA Otolaryngol Head Neck Surg; 2023 Sep; 149(9):849-850. PubMed ID: 37440250
[TBL] [Abstract] [Full Text] [Related]
16. Biphenotypic Sinonasal Sarcoma with a Novel PAX7::PPARGC1 Fusion: Expanding the Spectrum of Gene Fusions Beyond the pax3 Gene.
Bhele S; Chrisinger JSA; Farrell NF; Van Tine BA; Raptis CA; Chernock RD
Head Neck Pathol; 2023 Sep; 17(3):826-831. PubMed ID: 37378830
[TBL] [Abstract] [Full Text] [Related]
17. Extremity Rhabdomyosarcoma-An Integrated Clinicopathologic and Genomic Study to Improve Risk Stratification.
de Traux de Wardin H; Xu B; Dermawan JK; Smith MH; Wolden SL; Antonescu CR; Wexler LH
JCO Precis Oncol; 2023 Jun; 7(1):e2200705. PubMed ID: 37315267
[TBL] [Abstract] [Full Text] [Related]
18. Rhabdomyosarcomas are oncogene addicted to the activation of AVIL.
Xie Z; Janczyk PL; Shi X; Wang Q; Singh S; Cornelison R; Xu J; Mandell JW; Barr FG; Li H
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2118048119. PubMed ID: 37146302
[TBL] [Abstract] [Full Text] [Related]
19. Biphenotypic sinonasal sarcoma-A recently described entity with many mimics: A case report.
Ingle A; Mahendra N; Gopal Reddy GV
Indian J Pathol Microbiol; 2023; 66(2):396-399. PubMed ID: 37077095
[TBL] [Abstract] [Full Text] [Related]
20. Biphenotypic Sinonasal Sarcoma: Case Reports of Diagnostic Findings and Clinical Management of 3 Cases.
Augustin Y; Zaidi S; Jones RL; Benson C; Simcock R; Fisher C; Thway K; Hallin M; Miah AB
Anticancer Res; 2023 Apr; 43(4):1581-1589. PubMed ID: 36974788
[TBL] [Abstract] [Full Text] [Related]
[Next]
